Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Immucell Corp as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 28
- +3 vs. Q1 2024
- Shares held
- 1.15M
- +130.7K (+12.8%) vs. Q1 2024
- Total value
- $5.56M
- +$162.8K (+3.0%) vs. Q1 2024
- New holders
- 3
- 8 more added
- Sold out
- 0
- 8 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ICCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.4M |
| Q1 2026 | 27 | $8.67M |
| Q4 2025 | 26 | $7.87M |
| Q3 2025 | 27 | $8.08M |
| Q2 2025 | 25 | $9.00M |
| Q1 2025 | 27 | $5.79M |
| Q4 2024 | 27 | $6.21M |
| Q3 2024 | 22 | $4.27M |
| Q2 2024 | 28 | $5.56M |
| Q1 2024 | 25 | $5.39M |
| Q4 2023 | 28 | $5.31M |
| Q3 2023 | 30 | $5.47M |
| Q2 2023 | 31 | $5.32M |
| Q1 2023 | 30 | $5.42M |
| Q4 2022 | 26 | $5.41M |
| Q3 2022 | 26 | $7.26M |
| Q2 2022 | 29 | $8.53M |
| Q1 2022 | 27 | $9.18M |
| Q4 2021 | 29 | $7.04M |
| Q3 2021 | 28 | $8.05M |
| Q2 2021 | 28 | $7.45M |
| Q1 2021 | 28 | $7.20M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Immucell Corp; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 225,595 | $1.09M | 0.00% | +9,268+4.3% | Added |
| Cresset Asset Management, LLC | 207,212 | $1.00M | 0.00% | +103,606+100.0% | Added |
| Renaissance Technologies LLC | 125,589 | $609.1K | 0.00% | +700+0.6% | Added |
| Bleichroeder LP | 101,594 | $492.7K | 0.15% | 00.0% | Unchanged |
| Morgan Stanley | 66,816 | $324.1K | 0.00% | +2,100+3.2% | Added |
| Dimensional Fund Advisors LP | 66,069 | $320.4K | 0.00% | +2,668+4.2% | Added |
| Shufro Rose & Co LLC | 62,408 | $302.7K | 0.02% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 55,698 | $270.2K | 0.00% | +2,485+4.7% | Added |
| Overbrook Management Corp | 32,857 | $159.4K | 0.04% | 00.0% | Unchanged |
| Strategic Financial Services, Inc, | 31,000 | $150.3K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 28,561 | $138.5K | 0.00% | −1,434−4.8% | Reduced |
| Citadel Advisors LLC | 23,746 | $115.2K | 0.00% | +23,746 | New |
| HighTower Advisors, LLC | 21,354 | $103.0K | 0.00% | −100−0.5% | Reduced |
| Susquehanna International Group, LLP | 20,844 | $101.1K | 0.00% | −4,369−17.3% | Reduced |
| Prosperity Planning, Inc. | 16,000 | $77.6K | 0.03% | 00.0% | Unchanged |
| BlackRock Inc. | 13,764 | $66.8K | 0.00% | −1,091−7.3% | Reduced |
| Wealth Effects LLC | 12,917 | $62.6K | 0.02% | −2,500−16.2% | Reduced |
| Mesirow Financial Investment Management, Inc. | 12,178 | $59.1K | 0.00% | 00.0% | Unchanged |
| Essex Financial Services, Inc. | 11,000 | $41.5K | 0.00% | 00.0% | Unchanged |
| HM Payson & Co | 6,000 | $29.1K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,675 | $13.0K | 0.00% | −1,775−39.9% | Reduced |
| Bank of America Corp | 2,077 | $10.1K | 0.00% | +45+2.2% | Added |
| Tower Research Capital LLC (TRC) | 1,767 | $8.57K | 0.00% | −236−11.8% | Reduced |
| Royal Bank of Canada | 123 | $1.00K | 0.00% | +65+112.1% | Added |
| Jones Financial Companies LLLP | 19 | $92 | 0.00% | +19 | New |
| JPMorgan Chase & Co | 13 | $63 | 0.00% | 00.0% | Unchanged |
| Innealta Capital, LLC | 1 | $5 | 0.00% | +1 | New |
| Wells Fargo & Company | 1 | $3 | 0.00% | −2,543−100.0% | Reduced |